Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$4.0 million.

  • Ligand Pharmaceuticals' Net Income towards Common Stockholders rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 142.16% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Net Income towards Common Stockholders of -$4.0 million as of FY2024, which was down 142.16% from -$1.7 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Net Income towards Common Stockholders peaked at -$1.7 million during FY2023, and registered a low of -$28.1 million during FY2022.
  • In the last 3 years, Ligand Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$4.0 million in 2024 and averaged -$11.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 94.08% in 2023, then crashed by 142.16% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Net Income towards Common Stockholders stood at -$9.6 million in 2020, then slumped by 100.51% to -$19.2 million in 2021, then slumped by 46.46% to -$28.1 million in 2022, then skyrocketed by 94.08% to -$1.7 million in 2023, then crashed by 142.16% to -$4.0 million in 2024.